Saint Michael's Medical Center
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1867-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.smmcnj.com
Clinical Trials
6
Active:1
Completed:4
Trial Phases
2 Phases
Phase 3:1
Phase 4:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 4
3 (75.0%)Phase 3
1 (25.0%)Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)
Phase 4
Active, not recruiting
- Conditions
- Human Immunodeficiency Virus
- Interventions
- Drug: Dolutegravir/Lamivudine
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Saint Michael's Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT04826562
- Locations
- 🇺🇸
Saint Michael's Medical Center, Newark, New Jersey, United States
Portal-724 MEMS for Medication Adherence Patients Taking HCV Medications
Completed
- Conditions
- Adherence
- First Posted Date
- 2016-08-08
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Saint Michael's Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT02858050
- Locations
- 🇺🇸
Saint Michael's Medical Center, Newark, New Jersey, United States
Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study
Phase 4
Completed
- Conditions
- Hepatitis C InfectionHIV Infection
- Interventions
- Drug: Sofosbuvir, Ribavirin, and Stribild
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2016-08-04
- Lead Sponsor
- Saint Michael's Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT02220868
- Locations
- 🇺🇸
Saint Michael's Medical Center, Newark, New Jersey, United States
Pro-calcitonin Marker as Indicator of Ischemia in Patients With Complicated Coronary Intervention.
- Conditions
- Coronary Disease
- First Posted Date
- 2012-06-01
- Last Posted Date
- 2013-02-22
- Lead Sponsor
- Saint Michael's Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT01609569
- Locations
- 🇺🇸
Saint Michael's Medical Center, Newark, New Jersey, United States
Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected Patients
- First Posted Date
- 2008-09-15
- Last Posted Date
- 2011-07-20
- Lead Sponsor
- Saint Michael's Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT00752037
- Locations
- 🇺🇸
Saint Michael's Medical Center, Newark, New Jersey, United States
- Prev
- 1
- 2
- Next
News
No news found